Dr. Johnson’s research is centered around the analysis of multiomic data using advanced analytical techniques. The Johnson Lab works on the development of artificial intelligence tools to identify high risk cell types and novel therapeutic targets, provides service in support of myeloma, Alzheimer’s disease, and cervical cancer teams, and supports industry partners including Indiana Biosciences Research Institute, Eli Lilly and Company, and Genentech. Dr. Johnson has partnered with AnalytiXIN faculty member Dr. Tae-Hwi Schwantes-An to run a pilot GWAS experiment on non-obese vs. obese diabetics to provide preliminary data for an R01 submission submitted jointly between IUSM and IBRI. They are also working on setting up a second study to analyze the effects of SNPs on the efficacy of Plavix vs. other blood thinners.

The support from AnalytiXIN has allowed Dr. Johnson to fund pilot projects that he has been able to utilize for data on R-1 applications, hire a post-doctoral researcher that is being trained in high dimensional data analysis, multiomics, and machine learning, and travel to professional conferences to collaborate with other experts in the field. One of the three papers that Dr. Johnson published during the reporting period in Nature Communications was in collaboration with external partner, Genentech.